Related Experiment Videos
Somatostatin-receptor imaging in lymphoma
S J Goldsmith1, H A Macapinlac, J P O'Brien
1Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Seminars in Nuclear Medicine
|July 1, 1995
Summary
111In-DTPA-pentetreotide (Octreoscan) can detect lymphoma tissue, aiding in staging. However, its results are not consistently predictive, so it is not recommended over current imaging methods.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiology
Background:
- Lymphoma staging relies on disease extent and histopathology.
- Radiological methods like CT assess lymph node size for staging.
- Lymphomatous tissue exhibits high-density somatostatin receptors.
Purpose of the Study:
- To evaluate the utility of 111In-DTPA-pentetreotide (Octreoscan) for lymphoma staging.
- To determine if Octreoscan improves the accuracy of detecting lymphomatous tissue.
Main Methods:
- Patients with Hodgkin's or non-Hodgkin's lymphoma underwent Octreoscan imaging.
- The study assessed the ability of Octreoscan to identify lymphomatous tissue.
Main Results:
- Octreoscan imaging is safe and can identify both Hodgkin's and non-Hodgkin's lymphoma involvement.
- The diagnostic performance of Octreoscan was not uniformly predictive of disease involvement.
Conclusions:
- Routine use of Octreoscan is not recommended to replace current anatomic imaging methods for lymphoma staging.
- Further research is needed to understand the significance of in vivo somatostatin receptor detection in lymphoma.